JP2022177119A5 - - Google Patents

Download PDF

Info

Publication number
JP2022177119A5
JP2022177119A5 JP2022144243A JP2022144243A JP2022177119A5 JP 2022177119 A5 JP2022177119 A5 JP 2022177119A5 JP 2022144243 A JP2022144243 A JP 2022144243A JP 2022144243 A JP2022144243 A JP 2022144243A JP 2022177119 A5 JP2022177119 A5 JP 2022177119A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
administration
drug
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022144243A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022177119A (ja
JP7654604B2 (ja
Filing date
Publication date
Priority claimed from JP2021557408A external-priority patent/JP7142173B2/ja
Application filed filed Critical
Publication of JP2022177119A publication Critical patent/JP2022177119A/ja
Publication of JP2022177119A5 publication Critical patent/JP2022177119A5/ja
Priority to JP2025044178A priority Critical patent/JP2025098099A/ja
Application granted granted Critical
Publication of JP7654604B2 publication Critical patent/JP7654604B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022144243A 2019-12-06 2022-09-12 ブルトン型チロシンキナーゼ阻害剤の投薬 Active JP7654604B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025044178A JP2025098099A (ja) 2019-12-06 2025-03-19 ブルトン型チロシンキナーゼ阻害剤の投薬

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962944674P 2019-12-06 2019-12-06
US62/944,674 2019-12-06
US202063077996P 2020-09-14 2020-09-14
US63/077,996 2020-09-14
US202063109698P 2020-11-04 2020-11-04
US63/109,698 2020-11-04
JP2021557408A JP7142173B2 (ja) 2019-12-06 2020-12-03 ブルトン型チロシンキナーゼ阻害剤の投薬
PCT/US2020/063089 WO2021113497A1 (en) 2019-12-06 2020-12-03 Dosing of a bruton's tyrosine kinase inhibitor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021557408A Division JP7142173B2 (ja) 2019-12-06 2020-12-03 ブルトン型チロシンキナーゼ阻害剤の投薬

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025044178A Division JP2025098099A (ja) 2019-12-06 2025-03-19 ブルトン型チロシンキナーゼ阻害剤の投薬

Publications (3)

Publication Number Publication Date
JP2022177119A JP2022177119A (ja) 2022-11-30
JP2022177119A5 true JP2022177119A5 (cg-RX-API-DMAC7.html) 2023-10-31
JP7654604B2 JP7654604B2 (ja) 2025-04-01

Family

ID=73854977

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021557408A Active JP7142173B2 (ja) 2019-12-06 2020-12-03 ブルトン型チロシンキナーゼ阻害剤の投薬
JP2022144243A Active JP7654604B2 (ja) 2019-12-06 2022-09-12 ブルトン型チロシンキナーゼ阻害剤の投薬
JP2025044178A Pending JP2025098099A (ja) 2019-12-06 2025-03-19 ブルトン型チロシンキナーゼ阻害剤の投薬

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021557408A Active JP7142173B2 (ja) 2019-12-06 2020-12-03 ブルトン型チロシンキナーゼ阻害剤の投薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025044178A Pending JP2025098099A (ja) 2019-12-06 2025-03-19 ブルトン型チロシンキナーゼ阻害剤の投薬

Country Status (10)

Country Link
US (1) US12551463B2 (cg-RX-API-DMAC7.html)
EP (1) EP4069219A1 (cg-RX-API-DMAC7.html)
JP (3) JP7142173B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220100992A (cg-RX-API-DMAC7.html)
CN (1) CN115175677A (cg-RX-API-DMAC7.html)
AU (2) AU2020397034B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022009716A2 (cg-RX-API-DMAC7.html)
IL (1) IL292882B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022006631A (cg-RX-API-DMAC7.html)
WO (1) WO2021113497A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3108065C (en) 2018-07-31 2025-10-07 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
KR20220100992A (ko) * 2019-12-06 2022-07-18 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 투여

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US20150291554A1 (en) 2012-11-02 2015-10-15 Pfizer Inc. Bruton's Tyrosine Kinase Inhibitors
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
CN114605327B (zh) * 2015-12-16 2025-03-11 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
WO2017132474A1 (en) 2016-01-30 2017-08-03 Newave Pharmaceutical Inc. Bcl-2 inhibitors
KR102376764B1 (ko) 2016-08-05 2022-03-18 더 리젠츠 오브 더 유니버시티 오브 미시건 Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물
CN110177788B (zh) 2017-01-07 2023-03-24 重庆复创医药研究有限公司 作为bcl-2选择性凋亡诱导剂的化合物
SI3612531T1 (sl) 2017-04-18 2022-11-30 Shanghai Fochon Pharmaceutical Co., Ltd. Sredstva, ki sprožajo apoptozo
JP2020528061A (ja) 2017-07-26 2020-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト BET阻害剤、Bcl−2阻害剤及び抗CD20抗体を用いた併用療法
IL316472A (en) 2018-01-10 2024-12-01 Recurium Ip Holdings Llc Benzamide compounds
CN112437772B (zh) 2018-04-29 2023-11-21 百济神州有限公司 Bcl-2抑制剂
CA3108065C (en) 2018-07-31 2025-10-07 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
KR20220100992A (ko) * 2019-12-06 2022-07-18 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 투여

Similar Documents

Publication Publication Date Title
JP2023041862A5 (cg-RX-API-DMAC7.html)
JP2022180461A5 (cg-RX-API-DMAC7.html)
JP2022537551A5 (cg-RX-API-DMAC7.html)
JP2024074963A5 (cg-RX-API-DMAC7.html)
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
CN107260695A (zh) 硝唑尼特的控制释放药物剂型
CA2665841A1 (en) Pharmaceutical compositions
JP2021504384A5 (cg-RX-API-DMAC7.html)
JP2018507243A5 (cg-RX-API-DMAC7.html)
JP2024507810A5 (cg-RX-API-DMAC7.html)
JP2024527023A5 (cg-RX-API-DMAC7.html)
RU2010109359A (ru) Азитромицин для лечения кожных заболеваний
JP2023522415A5 (cg-RX-API-DMAC7.html)
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2016505050A5 (cg-RX-API-DMAC7.html)
JP2004525143A5 (cg-RX-API-DMAC7.html)
JP2025511402A5 (cg-RX-API-DMAC7.html)
JP2022553888A5 (cg-RX-API-DMAC7.html)
JP2024531799A5 (cg-RX-API-DMAC7.html)
JP2004091473A (ja) 色素沈着改善治療薬
BR112019026029A2 (pt) Formulações farmacêuticas orais de remogliflozina
IL292882A (en) Dosage of Bruton's tyrosine kinase inhibitor
CN113557016A (zh) 衣壳组装调节剂固体配制品
US20210283096A1 (en) Methods of treating obesity in responder and non-responder populations
RU2003100081A (ru) Способы и композиции, в которых используется сулодексид, для лечения диабетической нефропатии